This inventor holds 4 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: National Institute of Health and Medical Research, Centre National De La Recherche Scientifique, Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris. Active years: 2017-2025.
Company Filing History:
4 out of 1,853 
3 out of 5,383 
2 out of 105 
Years Active: 2017-2025
Title: Georgia Afonso: Innovator in Diabetes Research
Introduction
Georgia Afonso is a prominent inventor based in Paris, France. She has made significant contributions to the field of diabetes research, particularly in understanding and treating type 1 diabetes. With a total of 4 patents to her name, Afonso's work is paving the way for innovative diagnostic and therapeutic approaches.
Latest Patents
Afonso's latest patents include groundbreaking work on antigenic peptides. One of her notable inventions is focused on "Antigenic Peptides Deriving from Secretogranin V and Uses Thereof for the Diagnosis and Treatment of Type 1 Diabetes." Another significant patent involves "Antigenic Peptides Deriving from Urocortin 3 and Uses Thereof for the Diagnosis and Treatment of Type 1 Diabetes." This research highlights the role of inflammatory cytokines in increasing β-cell peptide presentation, which is crucial for understanding autoimmune β-cell destruction in type 1 diabetes.
Career Highlights
Throughout her career, Georgia Afonso has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paris Descartes. Her research has been instrumental in identifying novel β-cell antigens, which are vital for developing new diagnostic and treatment strategies for type 1 diabetes.
Collaborations
Afonso has collaborated with notable colleagues in her field, including Roberto Mallone and Sergio Gonzalez-Duque. These partnerships have further enhanced her research and contributed to the advancement of diabetes treatment.
Conclusion
Georgia Afonso is a trailblazer in diabetes research, with her innovative patents and collaborations significantly impacting the field. Her work continues to inspire advancements in the diagnosis and treatment of type 1 diabetes.